Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that dMMR status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Colorectal Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.
This statement is based on a regulatory approval from the Health Service Executive:
Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.